Elio Mazzone1,2,3, Sophie Knipper4,5, Francesco A Mistretta4,6, Zhe Tian4, Carlotta Palumbo4,7, Denis Soulieres4,8, Ottavio De Cobelli6, Francesco Montorsi9,10, Shahrokh F Shariat11, Fred Saad4,12, Alberto Briganti9,10, Pierre I Karakiewicz4,11. 1. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada. eliomazzone@gmail.com. 2. Division of Experimental Oncology/Unit of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy. eliomazzone@gmail.com. 3. Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, MI, Italy. eliomazzone@gmail.com. 4. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada. 5. Martini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 6. Department of Urology, European Institute of Oncology, Milan, Italy. 7. Department of Urology, Spedali Civili Hospital, University of Brescia, Brescia, Italy. 8. Division of Medical Oncology, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada. 9. Division of Experimental Oncology/Unit of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy. 10. Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, MI, Italy. 11. Department of Urology, Medical University of Vienna, Vienna, Austria. 12. Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada.
Abstract
BACKGROUND: The International Germ Cell Consensus Classification (IGCCC) is the recommended stratification scheme for newly diagnosed metastatic seminoma (mSGCT) and non-seminoma germ cell tumor (mNSGCT) patients. However, a contemporary North-American population-based validation has never been completed and represented our focus. MATERIALS AND METHODS: We identified mSGCT and mNSGCT patients within the SEER database (2004-2015). The IGCCC criteria were used for stratification into prognostic groups. Kaplan-Meier (KM) derived actuarial 5-year overall survival (OS) rates were calculated. In addition, cumulative incidence plots tested cancer-specific (CSM) and other-cause mortality (OCM) rates. RESULTS: Of 321 mSGCT patients, 190 (59.2%) and 131 (40.8%), respectively, fulfilled good and intermediate prognosis criteria. Of 803 mNSGCT patients, 209 (26.1%), 100 (12.4%), and 494 (61.5%), respectively, fulfilled good, intermediate, and poor prognosis criteria. In mSGCT patients, actuarial KM derived 5-year OS was 87% and 78% for, respectively, good and intermediate prognosis groups (p = 0.02). In cumulative incidence analyses, statistically significant differences were recorded for CSM but not for OCM between good versus intermediate prognosis groups. In mNSGCT patients, actuarial KM derived 5-year OS was 89%, 75% and 60% for, respectively, good, intermediate, and poor prognosis groups (p < 0.001). In cumulative incidence analyses, statistically significant differences were recorded for both CSM and OCM between good, intermediate, and poor prognosis groups. CONCLUSIONS: Our findings represent the first population-based validation of the IGCCC in contemporary North-American mSGCT and mNSGCT patients. The recorded OM rates closely replicate those of the original publication, except for better survival of poor prognosis mNSGCT patients.
BACKGROUND: The International Germ Cell Consensus Classification (IGCCC) is the recommended stratification scheme for newly diagnosed metastatic seminoma (mSGCT) and non-seminoma germ cell tumor (mNSGCT) patients. However, a contemporary North-American population-based validation has never been completed and represented our focus. MATERIALS AND METHODS: We identified mSGCT and mNSGCT patients within the SEER database (2004-2015). The IGCCC criteria were used for stratification into prognostic groups. Kaplan-Meier (KM) derived actuarial 5-year overall survival (OS) rates were calculated. In addition, cumulative incidence plots tested cancer-specific (CSM) and other-cause mortality (OCM) rates. RESULTS: Of 321 mSGCT patients, 190 (59.2%) and 131 (40.8%), respectively, fulfilled good and intermediate prognosis criteria. Of 803 mNSGCT patients, 209 (26.1%), 100 (12.4%), and 494 (61.5%), respectively, fulfilled good, intermediate, and poor prognosis criteria. In mSGCT patients, actuarial KM derived 5-year OS was 87% and 78% for, respectively, good and intermediate prognosis groups (p = 0.02). In cumulative incidence analyses, statistically significant differences were recorded for CSM but not for OCM between good versus intermediate prognosis groups. In mNSGCT patients, actuarial KM derived 5-year OS was 89%, 75% and 60% for, respectively, good, intermediate, and poor prognosis groups (p < 0.001). In cumulative incidence analyses, statistically significant differences were recorded for both CSM and OCM between good, intermediate, and poor prognosis groups. CONCLUSIONS: Our findings represent the first population-based validation of the IGCCC in contemporary North-American mSGCT and mNSGCT patients. The recorded OM rates closely replicate those of the original publication, except for better survival of poor prognosis mNSGCT patients.
Entities:
Keywords:
Chemotherapy; International Germ Cell Consensus Classification (IGCCC); Metastatic testicular cancer; Non-seminoma germ cell tumor of the testis; SEER program; Seminoma germ cell tumor of the testis
Authors: Sven-Erik Olofsson; Torgrim Tandstad; Mats Jerkeman; Olav Dahl; Olof Ståhl; Olbjørn Klepp; Roy M Bremnes; Gabriella Cohn-Cedermark; Carl W Langberg; Anna Laurell; Arne Solberg; Ulrika Stierner; Rolf Wahlqvist; Hans Wijkström; Harald Anderson; Eva Cavallin-Ståhl Journal: J Clin Oncol Date: 2011-04-11 Impact factor: 44.544
Authors: C Albany; N Adra; A C Snavely; C Cary; T A Masterson; R S Foster; K Kesler; T M Ulbright; L Cheng; M Chovanec; F Taza; K Ku; M J Brames; N H Hanna; L H Einhorn Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: Máire A Duggan; William F Anderson; Sean Altekruse; Lynne Penberthy; Mark E Sherman Journal: Am J Surg Pathol Date: 2016-12 Impact factor: 6.394
Authors: Felix Preisser; Marco Bandini; Elio Mazzone; Sebastiano Nazzani; Michele Marchioni; Zhe Tian; Fred Saad; Raisa S Pompe; Shahrokh F Shariat; Hans Heinzer; Francesco Montorsi; Hartwig Huland; Markus Graefen; Derya Tilki; Pierre I Karakiewicz Journal: Eur Urol Focus Date: 2018-05-22
Authors: A Horwich; D T Sleijfer; S D Fosså; S B Kaye; R T Oliver; M H Cullen; G M Mead; R de Wit; P H de Mulder; D P Dearnaley; P A Cook; R J Sylvester; S P Stenning Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: Maxine Sun; Firas Abdollah; Lars Budaüs; Daniel Liberman; Zhe Tian; Monica Morgan; Rupinder Johal; Jan Schmitges; Shahrokh F Shariat; Francesco Montorsi; Markus Greafen; Paul Perrotte; Pierre I Karakiewicz Journal: Ann Surg Oncol Date: 2011-04-21 Impact factor: 5.344
Authors: G Gandaglia; A Becker; Q-D Trinh; F Abdollah; J Schiffmann; F Roghmann; Z Tian; F Montorsi; A Briganti; P I Karakiewicz; M Sun Journal: Eur J Surg Oncol Date: 2013-09-25 Impact factor: 4.424
Authors: Alexander I Rolevich; Denis M Borodin; Anton N Rabcheuski; Tatsiana A Ivanitskaya; Sviataslau A Semenov; Liudmila V Artsiushkevich; Alena V Sukalinskaya; Edvard A Zhavrid; Sergei A Krasny; Natalia E Konoplya; Sergey L Polyakov Journal: JCO Glob Oncol Date: 2021-01
Authors: Michael J Hwang; Ameer Hamza; Miao Zhang; Shi-Ming Tu; Louis L Pisters; Bogdan Czerniak; Charles C Guo Journal: Am J Surg Pathol Date: 2022-01-01 Impact factor: 6.298